UNICO AMERICAN CORP: Nasdaq/NYSE listing notice — Unico American receives Nasdaq delisting notice for late 10-K filing

UNICO AMERICAN CORP

Nasdaq notified Unico on Apr 18, 2023 of noncompliance with Listing Rule 5250(c)(1) due to failure to file 2022 10-K by Mar 31, 2023 deadline.
Company has 60 calendar days (until June 20, 2023) to submit a plan to regain compliance; extension possible up to Oct 16, 2023.
No immediate effect on trading, but Nasdaq will broadcast noncompliance indicator; failure to comply could lead to delisting.
Unico's insurance subsidiary Crusader entered runoff in Sep 2021; premium financing and agency operations discontinued in 2021 and 2022 respectively.

item 3.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

UNICO AMERICAN CORP received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

April 18, 2023, Unico American Corporation (the “Company”) received a notice from the Listing Qualifications Department of The NASDAQ Stock Market LLC (“Nasdaq”) that the Company is noncompliant with the periodic filing requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure to file its Annual Report on Form 10-K for the year ended December 31, 2022 (the “Form 10-K”) with the Securities and Exchange Commission (the “SEC”) by the required due date (the “Notice”). As previously reported by the Company in its Notification of Late Fili

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001654954-23-005098

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.